Ciaranello, AndreaMorris, Bethany L.Walensky, RochelleWeinstein, MiltonAyaya, SamuelDoherty, KathleenLeroy, ValerianeHou, TaigeDesmonde, SophieLu, ZhigangNoubary, FarzadPatel, KunjalRamirez-Avila, LynnLosina, ElenaSeage III, George R.Freedberg, Kenneth2014-03-112013Ciaranello, A. L., B. L. Morris, R. P. Walensky, M. C. Weinstein, S. Ayaya, K. Doherty, V. Leroy, et al. 2013. “Validation and Calibration of a Computer Simulation Model of Pediatric HIV Infection.” PLoS ONE 8 (12): e83389. doi:10.1371/journal.pone.0083389. http://dx.doi.org/10.1371/journal.pone.0083389.1932-6203http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879230Background: Computer simulation models can project long-term patient outcomes and inform health policy. We internally validated and then calibrated a model of HIV disease in children before initiation of antiretroviral therapy to provide a framework against which to compare the impact of pediatric HIV treatment strategies. Methods: We developed a patient-level (Monte Carlo) model of HIV progression among untreated children <5 years of age, using the Cost-Effectiveness of Preventing AIDS Complications model framework: the CEPAC-Pediatric model. We populated the model with data on opportunistic infection and mortality risks from the International Epidemiologic Database to Evaluate AIDS (IeDEA), with mean CD4% at birth (42%) and mean CD4% decline (1.4%/month) from the Women and Infants’ Transmission Study (WITS). We internally validated the model by varying WITS-derived CD4% data, comparing the corresponding model-generated survival curves to empirical survival curves from IeDEA, and identifying best-fitting parameter sets as those with a root-mean square error (RMSE) <0.01. We then calibrated the model to other African settings by systematically varying immunologic and HIV mortality-related input parameters. Model-generated survival curves for children aged 0-60 months were compared, again using RMSE, to UNAIDS data from >1,300 untreated, HIV-infected African children. Results: In internal validation analyses, model-generated survival curves fit IeDEA data well; modeled and observed survival at 16 months of age were 91.2% and 91.1%, respectively. RMSE varied widely with variations in CD4% parameters; the best fitting parameter set (RMSE = 0.00423) resulted when CD4% was 45% at birth and declined by 6%/month (ages 0-3 months) and 0.3%/month (ages >3 months). In calibration analyses, increases in IeDEA-derived mortality risks were necessary to fit UNAIDS survival data. Conclusions: The CEPAC-Pediatric model performed well in internal validation analyses. Increases in modeled mortality risks required to match UNAIDS data highlight the importance of pre-enrollment mortality in many pediatric cohort studies.en-USJournal Article2014-03-1110.1371/journal.pone.0083389